Recent News

• 12.18.2024 - SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
• 11.06.2024 - SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
• 10.10.2024 - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Recent Filings

• 01.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.18.2024 - 144 Report of proposed sale of securities
• 11.06.2024 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.06.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2024 - 8-K Current report